A detailed history of Ensign Peak Advisors, Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 456,017 shares of TGTX stock, worth $14.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
456,017
Previous 71,017 542.12%
Holding current value
$14.7 Million
Previous $1.26 Million 744.5%
% of portfolio
0.02%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.21 - $25.28 $6.63 Million - $9.73 Million
385,000 Added 542.12%
456,017 $10.7 Million
Q1 2024

May 14, 2024

SELL
$13.02 - $21.3 $154,846 - $253,320
-11,893 Reduced 14.34%
71,017 $1.08 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $32,464 - $91,416
4,860 Added 6.23%
82,910 $1.42 Million
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $225,719 - $715,500
27,000 Added 52.89%
78,050 $652,000
Q1 2023

May 15, 2023

BUY
$10.23 - $19.34 $522,241 - $987,307
51,050 New
51,050 $767,000
Q3 2022

Nov 14, 2022

SELL
$4.57 - $8.4 $227,814 - $418,740
-49,850 Reduced 43.19%
65,580 $388,000
Q2 2022

Aug 12, 2022

BUY
$3.74 - $10.66 $313,711 - $894,160
83,880 Added 265.86%
115,430 $491,000
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $479,560 - $1.12 Million
31,550 New
31,550 $599,000
Q3 2021

Nov 12, 2021

SELL
$21.78 - $40.45 $951,851 - $1.77 Million
-43,703 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$41.61 - $54.3 $1.07 Million - $1.39 Million
-25,606 Reduced 36.94%
43,703 $2.11 Million
Q4 2020

Feb 12, 2021

BUY
$25.27 - $54.9 $25,270 - $54,900
1,000 Added 1.46%
69,309 $3.61 Million
Q3 2020

Nov 12, 2020

BUY
$18.49 - $27.24 $1.26 Million - $1.86 Million
68,309 New
68,309 $1.83 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.69B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.